

No Time to Waste: Real-world Repurposing of Generic Drugs as a Multifaceted Strategy against COVID-19

Moshe Rogosnitzky, Esther Berkowitz, Alejandro R Jadad

Submitted to: JMIRx Med
on: April 23, 2020

Disclaimer: © The authors. All rights reserved. This is a privileged document currently under peer-review/community review. Authors have provided JMIR Publications with an exclusive license to publish this preprint on its website for review purposes only. While the final peer-reviewed paper may be licensed under a CC BY license on publication, at this stage authors and publisher expressly prohibit redistribution of this draft paper other than for review purposes.

Table of Contents

Original Manuscript.....	4
---------------------------------	----------

Ahead Of Print
JMIR Publications

No Time to Waste: Real-world Repurposing of Generic Drugs as a Multifaceted Strategy against COVID-19

Moshe Rogosnitzky¹; Esther Berkowitz¹ MBChB, MA; Alejandro R Jadad² MD, DPhil, FRCPC, FCAHS, FRSA, LLD

¹Medinsight Research Institute Rehovot IL

²Program in Impactful Giving Dalla Lana School of Public Health University of Toronto Toronto CA

Corresponding Author:

Moshe Rogosnitzky
Medinsight Research Institute
Pekeris 4
Weizmann Science Park
Rehovot
IL

Abstract

Real-world drug repurposing – the immediate ‘off-label’ prescribing of drugs to address urgent clinical need – is an indispensable strategy gaining rapid traction in the current COVID-19 crisis. Although off-label prescribing (i.e. for a non-approved indication) is legal in most countries, it tends to shift the burden of liability or cost to physicians and patients, respectively. Nevertheless, in urgent public health crises it is often the only realistic source of meaningful potential solutions. To be considered for real-world repurposing, drug candidates should ideally have a track record of safety, affordability, and wide accessibility. Although thousands of such drugs are already available, the absence of a central repository of off-label uses presents a barrier to the immediate identification and selection of the safest potentially useful interventions. Using the current COVID-19 pandemic as an example, we provide a glimpse of the extensive literature that supports the rationale behind six generic drugs, in four classes, all of which are affordable, supported by decades of safety data, and pleiotropically target the underlying pathophysiology that makes COVID-19 so dangerous. Having previously fast-tracked this paper to publication in summary form, we now expand on why cimetidine or famotidine, dipyridamole, fenofibrate or bezafibrate, and sildenafil, are worth considering for patients with COVID-19. These examples also reveal the unlimited opportunity to future-proof our health by proactively mining, synthesizing, and cataloging the off-label treatment opportunities of thousands of safe, well established, and affordable generic drugs.

(JMIR Preprints 23/04/2020:19583)

DOI: <https://doi.org/10.2196/preprints.19583>

Preprint Settings

1) Would you like to publish your submitted manuscript as preprint?

✓ **Please make my preprint PDF available to anyone at any time (recommended).**

Please make my preprint PDF available only to logged-in users; I understand that my title and abstract will remain visible to all users.

Only make the preprint title and abstract visible.

No, I do not wish to publish my submitted manuscript as a preprint.

2) If accepted for publication in a JMIR journal, would you like the PDF to be visible to the public?

✓ **Yes, please make my accepted manuscript PDF available to anyone at any time (Recommended).**

Yes, but please make my accepted manuscript PDF available only to logged-in users; I understand that the title and abstract will remain visible to all users.

Yes, but only make the title and abstract visible (see Important note, above). I understand that if I later pay to participate in http://www.jmir.org/preprint/19583

Original Manuscript



No Time to Waste: Real-world Repurposing of Generic Drugs as a Multifaceted Strategy against COVID-19

Moshe Rogosnitzky¹; Esther Berkowitz, MBChB, MA¹; Alejandro R. Jadad, MD, DPhil FRCPC FCAHS FRSA LLD^{2,3}

1. MedInsight Research Institute, Pekeris 4, Weizmann Science Park, Rehovot, 7670204, Israel, Tel +97286220942 Email moshe@medinsight.org
2. Program in Impactful Giving, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
3. Department of Anesthesiology and Pain Medicine, Faculty of Medicine, University of Toronto, Toronto, Canada

Corresponding Author:

Moshe Rogosnitzky
Medinsight Research Institute
Pekeris 4
Weizmann Science Park
Rehovot
Israel
Phone: +972522945520
Email: moshe@medinsight.org

Abstract

Real-world drug repurposing – the immediate ‘off-label’ prescribing of drugs to address urgent clinical need – is an indispensable strategy gaining rapid traction in the current 2019 novel coronavirus (COVID-19) crisis. Although off-label prescribing (i.e. for a non-approved indication) is legal in most countries, it tends to shift the burden of liability or cost to physicians and patients, respectively. Nevertheless, in urgent public health crises it is often the only realistic source of meaningful potential solutions. To be considered for real-world repurposing, drug candidates should ideally have a track record of safety, affordability, and wide accessibility. Although thousands of such drugs are already available, the absence of a central repository of off-label uses presents a barrier to the immediate identification and selection of the safest potentially useful interventions. Using the current COVID-19 pandemic as an example, we provide a glimpse of the extensive literature that supports the rationale behind six generic drugs, in four classes, all of which are affordable, supported by decades of safety data, and pleiotropically target the underlying pathophysiology that makes COVID-19 so dangerous. Having previously fast-tracked this paper to publication in summary form, we now expand on why cimetidine/famotidine (histamine type-2 receptor antagonists), dipyridamole (antiplatelet agent), fenofibrate/bezafibrate (cholesterol/triglyceride lowering agents), and sildenafil (phosphodiesterase-5 inhibitor), are worth considering for patients with COVID-19 based on their antiviral, anti-inflammatory, renoprotective, cardioprotective, and anticoagulation properties. These examples also reveal the unlimited opportunity to future-proof public health by proactively mining, synthesizing, and cataloging the off-label treatment opportunities of thousands of safe, well established, and affordable generic drugs.

Background

Since the first report of an unknown cause of viral pneumonia in Wuhan, China in December 2019, followed by identification of Severe Acute Respiratory Syndrome coronavirus type 2 (SARS-CoV-2 and) designation of the pneumonia as 2019 novel coronavirus (COVID-19) disease, we have witnessed the rapid development of a pandemic that has become a global public health crisis. Although reported mortality rates are between <1% and 27% depending on factors including age, gender, health status, and geographic location, this is likely an underestimate due to under-reporting and limited serological testing [1]. With no approved preventive or therapeutic treatments available, the scale and human impact of the COVID-19 outbreak is daunting.

In this paper, we present candidates for a multifaceted approach to the management of COVID-19, based on repurposing tried and tested, affordable, widely available drugs with proven long-term safety, and mechanisms of action that address the underlying pathophysiology of the disease. Having recently published a short summary of our thesis [2], the current article expands on why cimetidine or famotidine (histamine type-2 receptor antagonists), dipyridamole (antiplatelet agent), fenofibrate or bezafibrate (cholesterol/triglycerides lowering agents), and sildenafil (phosphodiesterase-5 inhibitor) are worth considering for patients with COVID-19. The goal is to enable rapid introduction of potentially beneficial low-risk interventions. We also emphasize the urgency of redoubling efforts to mine, synthesize, and catalog the considerable existing body of evidence for promising treatments, in order to future-proof public health, based on robust science.

Pathophysiology of COVID-19

COVID-19 is characterized by prominent early respiratory signs and symptoms including fever, cough, fatigue, and shortness of breath that may deteriorate to acute respiratory distress syndrome (ARDS), coagulopathy, multi-organ failure, and other life-threatening sequelae (Table 1) [3,4]. On lung imaging, consolidation, ground glass opacity and pulmonary infiltration are evident [3].

Table 1: Common clinical findings, complications, and laboratory abnormalities in patients with laboratory-confirmed COVID-19

System [Reference]	Clinical finding	Prevalence
Respiratory [3,4]	Fever	79 - 98%
	Cough	58 - 79%
	Respiratory failure	54%
	Acute respiratory distress syndrome	30%
	Sputum production	12 - 28%
Cardiovascular [3]	Cardiac failure	23%
	Septic shock	20%
Multisystem [3,4]	Sepsis	59%
	Fatigue	20 - 44%
	Coagulopathy	19%
Laboratory abnormalities [3,4]	Lactate dehydrogenase >245 U/L	67 - 73%
	Procalcitonin <0.1 ng/mL	70%
	D-dimer >1 µg/mL	65 - 70%
	Lymphopenia	40 - 63%
	Aspartate aminotransferase > 40 U/L	37%
	Leucopenia	22 - 25%
	Raised C-reactive protein	Percentage data not available

However, SARS-CoV-2 has also been isolated from feces, urine, blood, and ophthalmic secretions [5], and COVID-19 affects extrapulmonary organs and systems in ways that contribute significantly to overall morbidity and mortality. In a retrospective cohort study of 191 hospitalized patients with COVID-19 in Wuhan, sepsis was observed in 112 (59%) patients admitted to the hospital, while respiratory failure (54%), ARDS (31%), heart failure (23%), and septic shock (20%) were reported in ≥20% of patients, significantly more frequently among

those who died than in survivors (all $p < .001$) [3]. Similarly, coagulopathy (19%), and acute cardiac (17%) and renal (15%) injury were widely observed, with significantly higher incidence in non-survivors [3]. The fact that underlying cardiovascular, pulmonary, and renal disease have been associated with significantly increased mortality in COVID-19 patients and that abnormalities of various plasma inflammatory biomarkers (such as lymphocyte count, C-reactive protein (CRP), procalcitonin, D-dimer, and aspartate aminotransferase) appears to be widespread [3,4,6,7] highlights the multisystemic nature of the disease and suggests that immune-mediated cytokine signaling and development of cytokine storm play a key role in driving disease progression [7].

Laboratory findings support the diverse effects of the SARS-CoV-2 virus, demonstrating, among other derangements, leukopenia, lymphopenia, and thrombocytopenia, and elevated lactate dehydrogenase, CRP and D-dimer, all of which are statistically significantly associated with more severe disease [3,4,6,8]. Viral load also correlates strongly with disease severity, and lung injury in particular [9], while virus-induced endothelial dysfunction contributes to acute cardiac events that are a recognized complication of COVID-19 [10]. Although little attention has focused specifically on disturbed coagulation, evidence suggests that COVID-19 leads to profoundly altered coagulation function, with raised D-dimer, fibrinogen, and fibrin/fibrinogen degradation products [11,12].

Potential therapies within the current pharmacopoeia

There has been widespread attention to repurposing of the antimalarial: chloroquine/hydroxychloroquine, the antibiotic: azithromycin and, most recently, the antiparasitic agent: ivermectin, for targeting COVID-19. All three drugs possess both anti-infective and immune-modulating properties [13–19]. While clinical evidence supporting their use either individually or in combination in COVID-19 have so far been inconclusive [13–19], partly due to methodological limitations, or are yet unavailable [20–22], this multi-targeted approach of utilizing the safest drugs with pleiotropic effects is essential to reduce the morbidity and mortality from COVID-19. Indeed, a large number of approved drugs have mechanisms of action that could be harnessed to address the pathophysiology of COVID-19. Ideal choices would be safe and widely available generic drugs that are affordable in any setting, and especially for underprivileged populations. Below we summarize the safety profiles and rationale for repurposing several generic drugs that have demonstrated antiviral, anti-inflammatory, and/or cardio-, lung- or renal protective effects. Some also lower elevated fibrinogen and D-dimer, which are associated with hypercoagulability and may contribute to the multiorgan failure seen in patients with COVID-19. Table 2 summarizes the physiological effects of these agents as they relate to potential benefits in patients with COVID-19.

Table 2: Approved indications and recognized physiological effects of drugs that could be considered for repurposing in patients with COVID-19

Drug [References]	Current indications	Proposed dose	Demonstrated effects							Notes
			A	B	C	D	E	F	G	
Cimetidine or famotidine [23-46]	Symptomatic management of GERD	<ul style="list-style-type: none"> ● Cimetidine 200mg four times daily ● Famotidine 20–40 mg twice daily 			✓		✓			<ul style="list-style-type: none"> ● Establish baseline prolactin levels and monitor periodically. ● May increase serum concentrations of other drugs. ● Reduces dipyridamole absorption ● Relevant trials: NCT04504240 and NCT04370262
Dipyridamole [47-77]	Antithrombotic following cardiac valve replacement	<ul style="list-style-type: none"> ● 75mg thrice daily ● OR 50-100 mg once weekly 	✓	✓	✓	✓	✓	✓		<ul style="list-style-type: none"> ● May cause headaches during the first week of use ● Taking with foods or antacids halves absorption ● Relevant trials: NCT04391179, NCT04424901, and NCT04410328

Fenofibrate or bezafibrate [80-97]	Dyslipidemia	<ul style="list-style-type: none"> ● Fenofibrate ≤200 mg/day ● Bezafibrate 400 mg daily 		✓	✓	✓	✓	✓	<ul style="list-style-type: none"> ● Significant reduction in D-dimer and fibrinogen usually seen in days. ● Relevant trial: NCT04517396
Sildenafil citrate [98-112]	Erectile dysfunction	<ul style="list-style-type: none"> ● 25 mg twice daily, on an empty stomach 		✓				✓	<ul style="list-style-type: none"> ✓● Avoid grapefruit juice (increases sildenafil levels) ● Cimetidine/famotidine increases sildenafil concentration. If combined, consider lower sildenafil dose – even 12.5 mg twice daily ● Relevant trials: NCT04304313 and NCT04489446
<p>Key for 'Demonstrated effects' columns:</p> <p>A - Preliminary efficacy in COVID-19 patients</p> <p>B - Anti-inflammatory effect</p> <p>C - Antiviral effect</p> <p>D - Anticoagulant effect</p> <p>E - Cardioprotective effect</p> <p>F - Renoprotective effect</p> <p>G - Lung protective effect</p>									

Cimetidine and famotidine

The histamine type-2 receptor antagonists (H₂RAs), cimetidine and famotidine, were approved by the United States (US) Food and Drug Administration (FDA) in 1977 and 1986, respectively, and both have been widely used for prevention and symptomatic management of gastroesophageal reflux disease (GERD) for decades [23]. Ranitidine, another commonly used H₂RA, will soon be largely unavailable in the US following a FDA recall based on high levels of a contaminant. Cimetidine is approved at daily doses of 200-400 mg for heartburn relief, and up to 1600 mg for short-term treatment of erosive GERD, while famotidine is approved at a dose of 10-20 mg twice daily (b.i.d.) for GERD, and 20-40 mg b.i.d. for erosive esophagitis [23]. Both drugs are available over-the-counter (OTC) in the U.S and much of the world, and are generally well-tolerated, with most adverse events reported in <1% of patients. Drug-drug interactions that may delay metabolism of other agents due to interaction with the cytochrome P450 system, limited anti-androgen effects, and stimulation of prolactin are recognized with cimetidine in particular. Prolactin levels should therefore be established at baseline and monitored periodically.

Antiviral and immunomodulatory activity

Beyond their role as gastric acid reducers, H₂RAs have powerful modulatory effects on innate and adaptive immunity by interfering with the effects of histamine on a range of leukocytes. As such, they reverse histamine-mediated immunosuppression by stimulating the effector functions of a wide range of T and B cells [24]. The resulting antiviral effects have been demonstrated in small studies in patients with herpes simplex virus (HSV) [25] and herpes zoster infection [26], and with human papillomavirus-related disorders [27]. In preclinical studies, cimetidine boosted immune cellular response when used as an adjuvant to viral vaccines for hepatitis B virus [28-31], and suppressed human immunodeficiency virus (HIV) replication *in vitro* [32]. Furthermore, intravenous ranitidine significantly increased the antibody response to vaccination in patients receiving tetanus toxoid before major abdominal surgery [33] and in patients with B-cell chronic lymphocytic leukemia receiving tetanus toxoid-conjugated Haemophilus influenzae type b vaccine [34,35]. Beyond antiviral effects, H₂RAs have shown immunomodulatory effects in a range of cancers and allergic diseases, bone resorption, and recovery from burn injury [24].

Cardiovascular protective effects

Histamine type-2 receptor antagonists also demonstrate a number of cardioprotective effects. A meta-analysis of 10 randomized controlled trials in patients with congestive heart failure, most of which used famotidine, showed that orally administered H₂RAs were associated with statistically significant negative inotropic and chronotropic

effects (reduction in heart rate vs. placebo; $p=.02$), and also significantly decreased blood pressure and increased cardiac efficiency, presumably reducing myocardial oxygen requirement [36]. In another study, in critically ill patients, a single intravenous infusion of cimetidine, 200 mg, reduced systolic, diastolic, and mean arterial BP, and raised heart rate [37]. High-dose intravenous cimetidine (200 mg four times daily (q.i.d.) administered after elective cardiac bypass surgery was also shown to reduce levels of proinflammatory mediators (neutrophil elastase, interleukin-8, C-reactive protein) with no adverse effects, suggesting the potential to improve cardiac outcomes under certain physiological conditions [38].

Furthermore, H₂RAs also strongly inhibit platelet aggregation *in vitro* [39,40] and ranitidine, in combination with hydrocortisone, has been shown to reduce complications after arterial thrombolysis in pediatric patients who developed arterial obstruction after cardiac catheterization [41]. These agents may therefore exert stabilizing effects on coagulation in patients with disturbed clotting function, the caveat being the potential for thrombocytopenia and/or hemolytic anemia [42–46].

Dipyridamole

The antiplatelet agent and phosphodiesterase inhibitor dipyridamole was first approved in 1961 and is indicated in the US at doses of 75-100 mg q.i.d., with warfarin, to decrease thrombotic risk following cardiac valve replacement [47]. It is also sold in the US as a combined product, Aggrenox® (aspirin 25 mg/extended-release dipyridamole 200 mg), which was approved in 1999 and is taken twice daily to reduce stroke risk [48]. Outside the US, including in Europe, dipyridamole is available as a single agent, and in Russia it is also approved as an antiviral agent [49]. Within the 200-400 mg daily dose range, dipyridamole is considered safe based on decades of clinical experience: adverse events are usually limited and transient, the most common being dizziness, gastrointestinal disturbance, headache and skin rash [50]. The pleiotropic effects of dipyridamole derive from increased intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanine monophosphate (cGMP), which lead to anti-inflammatory, antioxidant, anticoagulation, and vasodilatory effects [51].

Antiviral effects

Dipyridamole possesses very broad spectrum antiviral activity as shown in numerous preclinical studies that demonstrated efficacy, alone or as a potentiator of other agents, against HSV, HIV, varicella zoster, cytomegalovirus, and mengovirus, as well as a range of viruses from the picornavirus, togavirus, orthomyxovirus, paramyxovirus, and pox virus families [52–56]. Induction of interferon responses have been identified as an important contributory factor to its antiviral effects [57]. A number of clinical studies have confirmed the antiviral effects of dipyridamole which, at a dose of 8-100 mg weekly, significantly reduced the risk of acute respiratory diseases including influenza, when administered prophylactically to at-risk individuals [57–59].

Effects in patients with COVID-19

A recent study in patients with COVID-19 in China illustrated how dipyridamole suppressed SARS-CoV-2 replication *in vitro*; induced potent antiviral immunity and improved survival in a mouse model of pneumonia [60]. In a clinical study of 12 COVID-19 patients that was conducted alongside these preclinical investigations and reported within the same publication, dipyridamole increased lymphocyte and platelet counts, decreased D-dimer levels, and markedly improved clinical outcomes when dosed at 50 mg three times daily for one week. In this small but very promising study, three of the six patients with severe disease were discharged, and four (33%) mild cases achieved clinical remission. Data from an ongoing multicenter study examining dipyridamole in 460 patients with COVID-19 in China (ChiCTR2000030055) will add to our understanding [61].

Anti-inflammatory, antioxidant and endothelial protective effects

A large number of preclinical studies have demonstrated that dipyridamole limits oxidative stress in platelets and endothelial cells, inhibits release of pro-inflammatory cytokines, and reduces inflammatory responses, independent of its antiplatelet activity [51,62]. This has implications for a wide range of pathologies beyond thrombosis prevention. Examples include reduced brain endothelial injury after inflammatory and metabolic insult [63]. The combination of dipyridamole with prednisolone has been shown to lead to significant reductions in interferon- γ , interleukin-6, and C-reactive protein in subjects with periodontitis [64], and widening of the

therapeutic window of glucocorticoid activity [65]. This is due to the ability of dipyridamole to selectively potentiate the effects of prednisolone and other glucocorticoids. Dipyridamole was also shown to increase extracellular levels of the immune-dampening nucleoside, adenosine, and decrease CD4⁺ T cell activation by 11.1% ($p=0.006$), in patients with chronic HIV- infection receiving antiviral therapy [66].

Antihypercoagulation effects

Hypercoagulability is a potentially life-threatening complication of certain clinical conditions, and a serious risk during mechanical circulatory support. Besides its well- established antiplatelet effects, dipyridamole has shown efficacy as one component of a near-universal anticoagulant when administered in combination with citrate, theophylline, and adenosine (as CTAD) in veterinary practice [67,68] and in human subjects [69]. When combined with heparin or aspirin in small numbers of pediatric patients on circulatory support [70] or with disseminated intravascular coagulation (DIC) [71], dipyridamole has led to clinical recovery in the majority of subjects.

Cardioprotective effects

Adenosine serves as an endogenous cardioprotective agent. Disturbances of adenosine in the diseased myocardium include raised plasma levels and decreased gene expression of certain receptors in patients with chronic heart failure [72,73] and impaired vasodilation in patients with hyperhomocysteinemia [74]. By increasing adenosine levels *in vivo* using dipyridamole ≤ 300 mg daily, it was possible to improve numerous functional measures of disease severity in chronic heart failure [72,73] and restore adenosine-induced vasodilation in hyperhomocysteinemic patients [74]; highlighting the potential to augment endogenous cardioprotective mechanisms. The clinical effects of dipyridamole in mild to moderate chronic heart failure were also revealed in a trial that randomized 28 patients to their usual treatment with or without the addition of dipyridamole, 75 or 300 mg/day, for one year [75]. Cardiac ejection fraction, left ventricular systolic diameter, maximal oxygen consumption, and plasma B-type natriuretic peptide level were all statistically significantly improved versus baseline and control in dipyridamole-treated patients, in a broadly dose-dependent manner, indicating a role for supplementary dipyridamole in improving the pathophysiology of chronic heart failure.

Renoprotective effects

In patients with kidney disease, dipyridamole reduces proteinuria and improves renal function by inhibiting platelet activation and enhancing nitric oxide-induced vasodilation. A prospective study of >28,000 patients with advanced chronic kidney disease (CKD) in Taiwan found that dipyridamole significantly reduced the risk of progression to long-term dialysis and pre-dialysis death (hazard ratios 0.96 and 0.91, respectively; both $p<0.05$ versus non-use) [76]. In another large Taiwanese study in patients with advanced CKD, dipyridamole decreased the risk of progression to end-stage renal disease by approximately 15%, and reduced all-cause mortality by 23.5% ($p=0.001$) [77]. There is also evidence that the vascular renoprotective effects may benefit patients with immunoglobulin A nephropathy (when given with warfarin) [78] and protect against preeclampsia [79].

Fenofibrate and bezafibrate

The cholesterol-lowering agents fenofibrate and bezafibrate are indicated for the treatment of dyslipidemias. Fenofibrate is a peroxisome proliferator-activated receptor- α agonist that was approved in the US in 1993 and is indicated for treatment of primary hypertriglyceridemia, mixed dyslipidemia, and severe hypertriglyceridemia (up to 160 mg once daily) [80]. Abnormal liver tests, elevated liver enzymes and creatine phosphokinase, and rhinitis are the most frequent adverse events. Rare instances of myositis or rhabdomyolysis have been reported, and potentiation of coumarin anticoagulants can cause bleeding, so reduced anticoagulant dose is advised [80]. Bezafibrate is currently not approved for use in the US, but is commonly used in Europe.

Numerous preclinical studies support a role for fenofibrate in attenuating vascular endothelial dysfunction, oxidative stress, and inflammation across a range of organs and tissues, with clinical evidence of cardioprotection and some antiviral effects [81].

Antiviral effects

A meta-analysis of eight observational studies of fibrates, with or without statins, in patients with hepatitis C virus

infection, revealed a significant reduction in viral load, with bezafibrate demonstrating the greatest antiviral efficacy among the medications tested. The antiviral potency of bezafibrate was confirmed in both Asian and European study populations. Interestingly, the significant clinical effect was found despite the failure of *in vitro* studies to demonstrate a significant effect [82].

Anti-inflammatory effects

The anti-inflammatory properties of fibrates that underpin some of the macrovascular benefits also translate into improved clinical outcomes in patients with microvascular disease. In *in vitro* studies, fenofibrate demonstrated potentially protective effects on the renal and retinal microvasculature by suppressing inflammation and apoptosis in human glomerular microvascular cells [83,84] and reducing retinal microvascular inflammation [83,84]; while bezafibrate decreased the number of circulating pro-inflammatory monocytes in patients with type 2 diabetes [85]. A beneficial modulatory role for fenofibrate in renal fibrosis and inflammation has also been proposed, with further studies required to elucidate the mechanisms involved [81].

Cardioprotective effects

Preclinical studies provide evidence that fenofibrate can protect against cardiac ischemia-reperfusion injury and subsequent arrhythmias and heart failure; autoimmune myocarditis; and hypertension [81,86,87]. In the clinical setting, a meta-analysis of studies in which fibrates were used for primary prevention of atherosclerotic cardiovascular disease reported a significant decrease of 16% in the combined outcome of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke [88] while a 12% reduction in these outcomes was reported when fibrates were used in secondary prevention [89].

Anticoagulation effects

Robust data indicate that fibrates lower plasma fibrinogen levels to a statistically significant degree, independent of their lipid-lowering effects [90–95]. In a meta-analysis of 22 trials, representing >2700 participants, fibrates (fenofibrate and bezafibrate) demonstrated a significantly greater effect than statins in lowering plasma fibrinogen concentrations (weighted mean difference -40.7mg/dL, $p<.001$) [93]. Data from smaller studies focusing on the antihyperlipidemic effects of fibrates (fenofibrate 200 mg daily; bezafibrate 400 mg daily) show concurrent, statistically significant reductions in plasma fibrinogen levels [90–92,94]. Of note is a study that reported an increase in fibrinogen levels among patients taking statins [94] which could be a concern in elderly patients with COVID-19, many of whom are likely to be taking statins.

In patients with metabolic syndrome, which represents a hypercoagulable state accompanied by inflammation and endothelial dysfunction, fenofibrate reduced concentrations of thrombin-activatable fibrinolysis inhibitor, improved endothelial function [96], and significantly reduced fibrinogen and D-dimer concentrations [97], suggesting potential anticoagulant and cardiovascular protective effects. This potential was borne out in a short-term randomized controlled trial, in patients with acute ST elevation myocardial infarction, in which bezafibrate lowered fibrinogen concentration more effectively than conventional therapy ($p<.001$), with significantly greater reductions in the incidence of angina (56% vs. 4%, $p<.001$) and left ventricular failure (24% vs. 4%, $p=.049$) [95].

Sildenafil citrate

The phosphodiesterase-5 inhibitor (PDE5 inhibitor), sildenafil citrate, is a vasodilator that was approved by the FDA in 1998 for the treatment of erectile dysfunction, at a dose of 25-100 mg once daily [98]. More recently, an indication for pulmonary arterial hypertension (PAH) was added in 2005, with oral dosing of 5 or 20 mg thrice daily or 2.5 or 10 mg as intravenous bolus [99]. In erectile dysfunction, orally administered sildenafil has an onset of action within 30 minutes, maximum effect at 1 hour, and duration of effect of 4-6 hours; in PAH, the pharmacodynamics are similar although peak effect occurs 1-2 hours after dosing, and BP levels return to baseline levels within 8 hours [98,99]. The most common dose-dependent adverse reactions ($\geq 5\%$) include headache, flushing, dyspepsia, visual disturbance, and nasal congestion. CYP3A4 inhibitors are known to potentiate sildenafil, while sildenafil potentiates the hypotensive effects of nitrates and alpha-blockers.

Sildenafil inhibits breakdown of cGMP through competitive binding at the phosphodiesterase binding site. It therefore influences platelet activation, proliferation of T cells, and production of proinflammatory cytokines,

leading to a broad range of anti-inflammatory, antioxidant, vasodilatory, and other actions in many body systems [100]. An ongoing phase 3 trial of sildenafil, 100 mg daily for 14 days, in patients with COVID-19 (NCT04304313) will help clarify its potential benefits in this disease [101].

Immunomodulatory effects

In vitro human studies indicate that sildenafil potentiates the ability of regulatory T cells to downregulate T effector cell proliferation, while clinical findings include reduced lymphocyte count and induction of malignant cell apoptosis in a patient with B-cell chronic lymphocytic leukemia, and in patients with Waldenstrom's macroglobulinemia [100]. It was hypothesized that these effects were mediated by synthesis and release of cytokines. Sustained increase in nitric oxide production, and decreased vascular inflammatory markers have also been reported in patients with type 2 diabetes receiving sildenafil [102,103].

Cardiovascular protective effects

One-time and long-term administration of PDE5 inhibitors in patients at high cardiovascular risk can improve endothelial function, reduce inflammatory mediators, and increase endothelial regenerative capacity, which may be sustained for several months following treatment discontinuation, with potential applications in a range of cardiovascular disorders [104,105]. Cardioprotective effects include improved symptoms and cardiac contractility in patients with systolic heart failure, reduced myocardial infarct size, reduced blood pressure, and limitation of ischaemia-driven ventricular arrhythmias, with reduction in cardiovascular events and mortality in high-risk patients [106–108]. In a British study that followed nearly 6,000 men with type 2 diabetes over 7.5 years, the use of PDE5 inhibitors was associated with lower mortality risk overall (adjusted hazard ratio 0.54, $p=0.002$) and in those with a history of acute myocardial infarction ($HR=0.60$, $p=0.001$) [108]. These effects are believed to result from improved pulmonary circulation, as well as direct action on the myocardium, independent of the vasculature [106].

Lung-protective effects

Studies demonstrating sildenafil's efficacy and tolerability in PAH continue to accrue, and a 2019 Cochrane systematic review and meta-analysis of 36 studies in nearly 3000 patients concluded that those with PAH who received PDE5 inhibitors were 22% less likely to die in the short-term than those receiving placebo [109]. Additionally, a network meta-analysis reported moderate level evidence that sildenafil may reduce mortality in idiopathic pulmonary fibrosis, an interstitial lung disease with high mortality [110]. A single case report of a 55-year old physician with an atypical respiratory infection and apparently normal pulmonary arterial blood pressure who experienced marked symptomatic and functional improvement within 24 hours of starting tadalafil highlights the potential benefits of PDE5 inhibitors in this indication [111].

Renoprotective effects

Preliminary evidence suggests that the clinical efficacy of PDE5 inhibitors in CKD extends beyond anti-hypertensive effects to active renoprotection. In preclinical studies, PDE5 inhibitors suppressed mesangial cell proliferation and extracellular matrix expansion, reduced renal cell apoptosis, and decreased oxidative stress and inflammation [107]. A *post hoc* examination of this class of medications in a randomized controlled study also revealed improved kidney function and functional capacity, and a trend towards reduced mortality, in patients with PAH who received sildenafil treatment [112]. Few, if any, clinical studies of PDE5 inhibitors in patients with acute kidney disease have been published. Ongoing clinical trials (such as NCT04304313) will shed further light on this and may reveal information that could be applied in the treatment of patients with COVID-19 [101].

Conclusions

Under the extraordinary COVID-19 pandemic conditions that have brought the world to the brink of an irreversible crisis, time is of the essence for the success of life-saving efforts. Until a SARS-CoV-2 vaccine is developed, the urgency of finding safe and effective treatments cannot be overstated. To ensure that patients with COVID-19 have rapid access to safe treatments, and to ensure responsible use of available resources, it would be wise to mine the existing pharmacopeia for safe generic drugs that address the pathophysiologies underlying COVID-19. Moreover, beyond the current emergency there remains the likelihood of future re-emergence of

another SARS-CoV or similar virus. The efforts we make now to facilitate access to information on the off-label applications of well-understood drugs regardless of the manner in which the information has been discovered are an investment in our future health, as well as addressing current needs. While clinical trials to assess efficacy will be important in due course, judicious use of one or more of these approved drugs, with caution towards potential interactions with concomitant medications, represents a rational and ethical approach that may prove effective in the short-term. There is no time to waste and little to lose.

Epilogue

Since the initial submission of this article as a preprint in April 2020, new developments and evidence have emerged that further supports the therapeutic potential of the drugs proposed in this paper for use in the treatment of COVID-19. The new developments and evidence are summarized below and are up to date as of August 31st, 2020.

Dipyridamole

Research aimed at assessing the therapeutic potential of dipyridamole continues. One major ongoing study in this regard is a phase 3 clinical trial (ClinicalTrials.gov identifier: NCT04410328) in which a total of 132 participants will be randomly divided into two equal groups with one group receiving Dipyridamole ER 200 mg and Aspirin 25 mg orally/enterally plus standard care and the other group receiving only standard care [113]. Researchers are also evaluating the effect of dipyridamole in two other ongoing clinical trials with a focus on determining the extent to which the drug can reduce excessive blood clotting [114] and treating respiratory tract infection and circulatory dysfunction caused by SARS-CoV-2 [115] in hospitalized COVID-19 patients.

Famotidine

The therapeutic potential of famotidine (combined with cetirizine) in COVID-19 was recently boosted by an American cohort study evaluating the efficacy of dual-histamine blockade in patients with COVID-19. In the study, hospitalized COVID-19 patients with severe to critical symptoms were treated with cetirizine 10 mg and famotidine 20 mg b.i.d. in addition to standard care. This combination resulted in reductions in symptom progression when compared to published reports of COVID-19 patients [116]. The safety and efficacy of famotidine in COVID-19 patients is further supported by researchers in the US who documented a case series of 10 patients with COVID-19 who self-administered high-dose oral famotidine (80 mg thrice daily was the most frequent regimen used) for 11 days. All patients reported marked improvements in COVID-19-related symptoms suggesting that high-dose oral famotidine is well tolerated and associated with improved patient-reported outcomes in non-hospitalised patients with COVID-19 [117].

Another case series of 14 COVID-19 hospitalized patients from Beloit Memorial Hospital, USA, reports improvement in supplemental oxygen requirements, ground-glass computed tomography findings, and serum levels of lactate dehydrogenase, ferritin, C-reactive protein, D-dimer, and lymphocytes in patients who received famotidine 80 mg q.i.d. plus celecoxib (as adjuvant therapy) [118]. This treatment combination was associated with a 100% survival rate. Similar clinical improvements have also been reported by Freedberg et al among hospitalized COVID-19 patients [119]. Despite clinical evidence suggesting that famotidine may mitigate COVID-19, its mechanism of action remains a matter of debate. A recent study by Malone et al. in this regard suggests that the drug's therapeutic action in COVID-19 involves on-target histamine receptor-H2 activity, especially considering that the development of clinical symptoms of the disease involves dysfunctional mast cell activation and histamine release [120].

Fenofibrate

Researchers from Hebrew University of Jerusalem (Israel) and Icahn School of Medicine at Mount Sinai (USA) studied the metabolic rewiring induced by SARS-CoV-2 infection in bronchial epithelial cells using lung biopsy samples of COVID-19 patients. The researchers reported a significant metabolic response in SARS-CoV-2-infected lungs in addition to changes in lipid metabolism and the induction of inositol-requiring enzyme-1 and RNA-activated protein kinase pathways of endoplasmic stress. The study showed that fenofibrate reversed the metabolic changes induced by SARS-CoV-2, blocking viral production, and suppressing its pathogenesis in lung tissue [121].

Sildenafil

A recent systematic review carried out by researchers from the University of Rome, Italy, consolidates evidence

documenting any involvement of the NO-cGMP-PDE5 axis in the pathophysiology of COVID-19, presenting ongoing clinical trials aimed at modulating this axis, including the "sildEnafil administration in DiAbetic and dysmetaboLic patients with COVID-19" (DEDALO) trial [122]. Reviewed data indicates that PDE5 inhibitors could be effective in managing patients with COVID-19 by counteracting the Ang-II-mediated downregulation of AT-1 receptor; exhibiting action on monocyte switching, reducing pro-inflammatory cytokines, interstitial infiltration; and inhibiting the transition of endothelial and smooth muscle cells to mesenchymal cells in the pulmonary artery, preventing clotting and thrombotic complications. With sildenafil's low cost, well-established safety, wide availability, and efficacy arising from observational studies and clinical trials (including the new "Sildenafil in COVID-19" trial (ClinicalTrials.gov identifier: NCT04489446), it, and other PDE5 inhibitors, could potentially become key COVID-19 treatment options [122,123].



References

1. Johns Hopkins ABX Guide [Internet]. [cited 2020 Mar 31]. Available from: Auwaerter, Paul G. "Coronavirus COVID-19 (SARS-CoV-2)." Johns Hopkins ABX Guide, The Johns Hopkins University, 2017. Johns Hopkins Guide, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540747/all/Coronavirus_COVID_19_SARS_CoV_2_.
2. Rogosnitzky M, Berkowitz E, Jadad AR. Delivering benefits at speed through real-world repurposing of off-patent drugs: The COVID-19 pandemic as a case in point. *JMIR Public Health Surveill* [Internet]. 2020 May 13;6(2):e19199. Available from: <http://dx.doi.org/10.2196/19199>
3. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* [Internet]. 2020 Mar 28;395(10229):1054–62. Available from: [http://dx.doi.org/10.1016/S0140-6736\(20\)30566-3](http://dx.doi.org/10.1016/S0140-6736(20)30566-3)
4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* [Internet]. 2020 Feb 15;395(10223):497–506. Available from: [http://dx.doi.org/10.1016/S0140-6736\(20\)30183-5](http://dx.doi.org/10.1016/S0140-6736(20)30183-5)
5. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in different types of clinical specimens. *JAMA* [Internet]. 2020;323(18):1843–4. Available from: <http://dx.doi.org/10.1001/jama.2020.3786>
6. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. *Zhonghua Liu Xing Bing Xue Za Zhi* [Internet]. 2020 Feb 17;41(2):145–51. Available from: <http://dx.doi.org/10.3760/cma.j.issn.0254-6450.2020.02.003>
7. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system: A review. *JAMA Cardiol* [Internet]. 2020 Mar 27;5(7):831–40. Available from: <http://dx.doi.org/10.1001/jamacardio.2020.1286>
8. Zhang F, Yang D, Li J, Gao P, Chen T, Cheng Z, et al. Myocardial injury is associated with in-hospital mortality of confirmed or suspected COVID-19 in Wuhan, China: A single center retrospective cohort study. *medRxiv* [Internet]. 2020 Mar;1–11. Available from: <http://dx.doi.org/10.1101/2020.03.21.20040121>
9. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. *Sci China Life Sci* [Internet]. 2020 Mar;63(3):364–74. Available from: <http://dx.doi.org/10.1007/s11427-020-1643-8>
10. Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. *Cardiovasc Res* [Internet]. 2020 May 1;116(6):1097–100. Available from: <http://dx.doi.org/10.1093/cvr/cvaa078>
11. Han H, Yang L, Liu R, Liu F, Wu K-L, Li J, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. *Clin Chem Lab Med* [Internet]. 2020 Jun 25;58(7):1116–20. Available from: <http://dx.doi.org/10.1515/cclm-2020-0188>
12. Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. *J Med Virol* [Internet]. 2020 Jul;92(7):791–6. Available from: <http://dx.doi.org/10.1002/jmv.25770>
13. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *Biosci Trends* [Internet]. 2020 Mar 16;14(1):72–3. Available from: <http://dx.doi.org/10.5582/bst.2020.01047>
14. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents* [Internet]. 2020 Jul;56(1):105949. Available from: <http://dx.doi.org/10.1016/j.ijantimicag.2020.105949>
15. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Sevestre J, et al. Clinical and microbiological effect of a

- combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. *Travel Med Infect Dis* [Internet]. 2020 Mar;34:101663. Available from: <http://dx.doi.org/10.1016/j.tmaid.2020.101663>
16. Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. *MedRxiv* [Internet]. 2020;1–11. Available from: <http://dx.doi.org/10.1101/2020.03.22.20040758>
 17. Huang M, Tang T, Pang P, Li M, Ma R, Lu J, et al. Treating COVID-19 with Chloroquine. *J Mol Cell Biol* [Internet]. 2020 May 18;12(4):322–5. Available from: <http://dx.doi.org/10.1093/jmcb/mjaa014>
 18. Magagnoli J, Narendran S, Pereira F, Cummings TH, Hardin JW, Sutton SS, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19. *Med* [Internet]. 2020 Jun 5;1:1–14. Available from: <http://dx.doi.org/10.1016/j.medj.2020.06.001>
 19. Mahevas M, Tran V-T, Roumier M, Chabrol A, Paule R, Guillaud C, et al. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. *medRxiv* [Internet]. 2020 Apr;1–20. Available from: <http://dx.doi.org/10.1101/2020.04.10.20060699>
 20. Chaccour C, Hammann F, Ramón-García S, Regina Rabinovich N. Ivermectin and novel coronavirus disease (COVID-19): keeping rigor in times of urgency. *Am J Trop Med Hyg* [Internet]. 2020;102(6):1156–7. Available from: <http://dx.doi.org/10.4269/ajtmh.20-0271>
 21. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Res* [Internet]. 2020 Apr 3;178:104787. Available from: <http://dx.doi.org/10.1016/j.antiviral.2020.104787>
 22. Patrì A, Fabbrocini G. Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment? *J Am Acad Dermatol* [Internet]. 2020 Jun;82(6):e221. Available from: <http://dx.doi.org/10.1016/j.jaad.2020.04.017>
 23. Merck Manual Professional Version: Gastric acid reducers [Internet]. Available from: <https://www.merckmanuals.com/professional/gastrointestinal-disorders/gastritis-and-peptic-ulcer-disease/drug-treatment-of-gastric-acidity#v892554>
 24. Jafarzadeh A, Nemati M, Khorramdelazad H, Hassan ZM. Immunomodulatory properties of cimetidine: Its therapeutic potentials for treatment of immune-related diseases. *Int Immunopharmacol* [Internet]. 2019 May;70:156–66. Available from: <http://dx.doi.org/10.1016/j.intimp.2019.02.026>
 25. Kurzrock R, Auber M, Mavligit GM. Cimetidine therapy of herpes simplex virus infections in immunocompromised patients. *Clin Exp Dermatol* [Internet]. 1987 Sep;12(5):326–31. Available from: <http://dx.doi.org/10.1111/j.1365-2230.1987.tb02501.x>
 26. Kapińska-Mrowiecka M, Turowski G. [Efficacy of cimetidine in treatment of Herpes zoster in the first 5 days from the moment of disease manifestation]. *Pol Tyg Lek* [Internet]. 1996 Jun;51(23-26):338–9. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/9273526>
 27. Harcourt JP, Worley G, Leighton SE. Cimetidine treatment for recurrent respiratory papillomatosis. *Int J Pediatr Otorhinolaryngol* [Internet]. 1999 Dec 5;51(2):109–13. Available from: [http://dx.doi.org/10.1016/s0165-5876\(99\)00279-7](http://dx.doi.org/10.1016/s0165-5876(99)00279-7)
 28. Niu X, Yang Y, Wang J. Synergistic and additive effects of cimetidine and levamisole on cellular immune responses to hepatitis B virus DNA vaccine in mice. *Scand J Immunol* [Internet]. 2013 Feb;77(2):84–91. Available from: <http://dx.doi.org/10.1111/sji.12018>
 29. Xie X, Geng S, Liu H, Li C, Yang Y, Wang B. Cimetidine synergizes with Praziquantel to enhance the immune response of HBV DNA vaccine via activating cytotoxic CD8(+) T cell. *Hum Vaccin Immunother* [Internet]. 2014 Mar 18;10(6):1688–99. Available from: <http://dx.doi.org/10.4161/hv.28517>
 30. Zhang W, Wang J, Su B, Li R, Ding Z, Kang Y, et al. Cimetidine augments Th1/Th2 dual polarized immune

- responses to recombinant HBV antigens. Vaccine [Internet]. 2011 Jun 24;29(29-30):4862–8. Available from: <http://dx.doi.org/10.1016/j.vaccine.2011.03.091>
31. Wang J, Su B, Ding Z, Du X, Wang B. Cimetidine enhances immune response of HBV DNA vaccination via impairment of the regulatory function of regulatory T cells. Biochem Biophys Res Commun [Internet]. 2008 Aug 1;372(3):491–6. Available from: <http://dx.doi.org/10.1016/j.bbrc.2008.04.191>
 32. Bourinbaiar AS, Fruhstorfer EC. The effect of histamine type 2 receptor antagonists on human immunodeficiency virus (HIV) replication: Identification of a new class of antiviral agents [Internet]. Vol. 59, Life Sciences. 1996. p. PL365–70. Available from: [http://dx.doi.org/10.1016/s0024-3205\(96\)00553-x](http://dx.doi.org/10.1016/s0024-3205(96)00553-x)
 33. Nielsen HJ, Hammer JH, Moesgaard F, Heron I, Kehlet H. Ranitidine improves postoperative suppression of antibody response to preoperative vaccination. Surgery [Internet]. 1992 Jan;111(1):69–73. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/1728077>
 34. Van der Velden AMT, Van Velzen-Blad H, Claessen AME, Van der Griend R, Oltmans R, Rijkers GT, et al. The effect of ranitidine on antibody responses to polysaccharide vaccines in patients with B-cell chronic lymphocytic leukaemia. Eur J Haematol [Internet]. 2007 Jul;79(1):47–52. Available from: <http://dx.doi.org/10.1111/j.1600-0609.2007.00862.x>
 35. Jurlander J, de Nully Brown P, Skov PS, Henrichsen J, Heron I, Obel N, et al. Improved vaccination response during ranitidine treatment, and increased plasma histamine concentrations, in patients with B cell chronic lymphocytic leukemia. Leukemia [Internet]. 1995 Nov;9(11):1902–9. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/7475282>
 36. Zhang J, Cai W-K, Zhang Z, Wang P, Lin X-Q, Feng J, et al. Cardioprotective effect of histamine H2 antagonists in congestive heart failure: A systematic review and meta-analysis. Medicine [Internet]. 2018 Apr;97(15):e0409. Available from: <http://dx.doi.org/10.1097/MD.00000000000010409>
 37. Breuer HW, Hartung HJ, Goeckenjan G, Abendroth RR, Curtius JM, Trampisch HJ, et al. [Cimetidine and ranitidine in intensive care patients. Double-blind randomized cross-over study on intravenous administration: hemodynamics, plasma coagulation, blood gases and acid-base status]. Dtsch Med Wochenschr [Internet]. 1985 Jul 26;110(30):1151–6. Available from: <http://dx.doi.org/10.1055/s-2008-1068976>
 38. Tayama E, Hayashida N, Fukunaga S, Tayama K, Takaseya T, Hiratsuka R, et al. High-dose cimetidine reduces proinflammatory reaction after cardiac surgery with cardiopulmonary bypass. Ann Thorac Surg [Internet]. 2001 Dec;72(6):1945–9. Available from: [http://dx.doi.org/10.1016/s0003-4975\(01\)03225-8](http://dx.doi.org/10.1016/s0003-4975(01)03225-8)
 39. Nakamura K, Kariyazono H, Shinkawa T, Yamaguchi T, Yamashita T, Ayukawa O, et al. Inhibitory effects of H2-receptor antagonists on platelet function in vitro. Hum Exp Toxicol [Internet]. 1999 Aug;18(8):487–92. Available from: <http://dx.doi.org/10.1191/096032799678847069>
 40. Mikhailidis DP, Christofides J, Barradas MA, Jeremy JY, Dilawari J, Dandona P. The effect of cimetidine on platelet function: a study involving gastric fluid measurements. Agents Actions [Internet]. 1986 Oct;19(1-2):34–41. Available from: <http://dx.doi.org/10.1007/bf01977253>
 41. Noori N, Miri Aliabad G, Mohammadi M, Mahjoubifard M, Jahangiri Fard A. The effects of ranitidine and hydrocortisone on the complications of femoral artery obstruction treated by streptokinase following cardiac catheterization in pediatric patients with congenital heart diseases. Iran Red Crescent Med J [Internet]. 2013 Feb;15(2):117–21. Available from: <http://dx.doi.org/10.5812/ircmj.7248>
 42. Glotzbach RE. Cimetidine-induced thrombocytopenia. South Med J [Internet]. 1982 Feb;75(2):232–4. Available from: <http://dx.doi.org/10.1097/00007611-198202000-00030>
 43. Gentilini G, Curtis BR, Aster RH. An antibody from a patient with ranitidine-induced thrombocytopenia recognizes a site on glycoprotein IX that is a favored target for drug-induced antibodies. Blood [Internet]. 1998 Oct 1;92(7):2359–65. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/9746775>
 44. Gafter U, Zevin D, Komlos L, Livni E, Levi J. Thrombocytopenia associated with hypersensitivity to ranitidine: possible cross-reactivity with cimetidine. Am J Gastroenterol [Internet]. 1989 May;84(5):560–2. Available

from: <https://www.ncbi.nlm.nih.gov/pubmed/2719014>

45. Takimoto R, Mogi Y, Kura T, Niitsu Y. [Hemolytic anemia and thrombocytopenia induced by cimetidine: recurrence with ranitidine administration]. *Rinsho Ketsueki* [Internet]. 1997 Feb;38(2):124–8. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/9059066>
46. Hoste L, George I. Ranitidine-induced Thrombocytopenia in a Neonate – A Case Report and Review of Literature [Internet]. Vol. 24, *The Journal of Pediatric Pharmacology and Therapeutics*. 2019. p. 66–71. Available from: <http://dx.doi.org/10.5863/1551-6776-24.1.66>
47. Boehringer Ingelheim. Dipyridamole [Persantine]: Prescribing Information [Internet]. Boehringer Ingelheim International GmbH; 2019 Dec. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/012836s061lbl.pdf
48. Boehringer Ingelheim International GmbH. Aspirin/Extended-Release Dipyridamole [Aggrenox]: Highlights of prescribing information [Internet]. 2019 Dec. Available from: <https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Aggrenox%20Caps/Aggrenox.pdf>
49. Curantyl 25 (dipyridamole) prescribing information [Internet]. Russian Drug Register. 2005 [cited 2020 Apr 2]. Available from: https://pda.rlsnet.ru/tn_index_id_3874.htm#pokazaniya-preparata-kurantil-
50. Lette J, Tatum JL, Fraser S, Miller DD, Waters DD, Heller G, et al. Safety of dipyridamole testing in 73,806 patients: the Multicenter Dipyridamole Safety Study. *J Nucl Cardiol* [Internet]. 1995 Jan;2(1):3–17. Available from: [http://dx.doi.org/10.1016/s1071-3581\(05\)80003-0](http://dx.doi.org/10.1016/s1071-3581(05)80003-0)
51. Balakumar P, Nyo YH, Renushia R, Raaginey D, Oh AN, Varatharajan R, et al. Classical and pleiotropic actions of dipyridamole: Not enough light to illuminate the dark tunnel? *Pharmacol Res* [Internet]. 2014 Sep;87:144–50. Available from: <http://dx.doi.org/10.1016/j.phrs.2014.05.008>
52. Tonew M, Tonew E, Mentel R. The antiviral activity of dipyridamole. *Acta Virol* [Internet]. 1977 Mar;21(2):146–50. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/17283>
53. Tonew M, Dzeguze D. Dipyridamole, an inhibitor of mengovirus replication in FL and L cells. *Chemotherapy* [Internet]. 1977;23(3):149–58. Available from: <http://dx.doi.org/10.1159/000221983>
54. Tenser RB, Gaydos A, Hay KA. Inhibition of herpes simplex virus reactivation by dipyridamole. *Antimicrob Agents Chemother* [Internet]. 2001 Dec;45(12):3657–9. Available from: <http://dx.doi.org/10.1128/AAC.45.12.3657-3659.2001>
55. Patel SS, Szebeni J, Wahl LM, Weinstein JN. Differential inhibition of 2'-deoxycytidine salvage as a possible mechanism for potentiation of the anti-human immunodeficiency virus activity of 2',3'-dideoxycytidine by dipyridamole. *Antimicrob Agents Chemother* [Internet]. 1991 Jun;35(6):1250–3. Available from: <http://dx.doi.org/10.1128/aac.35.6.1250>
56. Snoeck R, Andrei G, Balzarini J, Reyman D, De Clercq E. Dipyridamole potentiates the activity of various acyclic nucleoside phosphonates against varicella-zoster virus, herpes simplex virus and human cytomegalovirus. *Antiviral Chem Chemother* [Internet]. 1994;5(5):312–21. Available from: <http://dx.doi.org/10.1177/095632029400500505>
57. Kuzmov K, Galabov AS, Radeva K, Kozhukharova M, Milanov K. [Epidemiological trial of the prophylactic effectiveness of the interferon inducer dipyridamole with respect to influenza and acute respiratory diseases]. *Zh Mikrobiol Epidemiol Immunobiol* [Internet]. 1985 Jun;(6):26–30. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/3898670>
58. Fedorova GI, Slepishkin AN. [Epidemiologic and economic efficacy of massive prophylaxis of influenza and other acute respiratory viral infections using curantyl in Moscow enterprises]. *Ter Arkh* [Internet]. 2002;74(11):18–21. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/12498118>
59. Guchev IA, Klochkov OI. [Dipyridamole prevention of outbreaks of respiratory infections in the homogeneous population]. *Klin Med* [Internet]. 2004;82(11):45–9. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/15656399>

60. Liu X, Li Z, Liu S, Sun J, Chen Z, Jiang M, et al. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19. *Acta Pharmaceutica Sinica B* [Internet]. 2020;10(7):1205–15. Available from: <http://dx.doi.org/10.1016/j.apsb.2020.04.008>
61. Chictr.org. Identifier ChiCTR2000030055, Multicenter study for the treatment of Dipyridamole with novel coronavirus pneumonia (COVID-19) [Internet]. Chinese Clinical Trial Registry. China: Chinese Clinical Trial Registry; 2020 [cited 2020 Aug 28]. Available from: <http://www.chictr.org.cn/showprojen.aspx?proj=49864>
62. Kim H-H, Liao JK. Translational therapeutics of dipyridamole. *Arterioscler Thromb Vasc Biol* [Internet]. 2008 Mar;28(3):s39–42. Available from: <http://dx.doi.org/10.1161/ATVBAHA.107.160226>
63. Guo S, Stins M, Ning M, Lo EH. Amelioration of inflammation and cytotoxicity by dipyridamole in brain endothelial cells. *Cerebrovasc Dis* [Internet]. 2010 Aug;30(3):290–6. Available from: <http://dx.doi.org/10.1159/000319072>
64. Renvert S, Lindahl C, Roos-Jansåker A-M, Lessem J. Short-term effects of an anti-inflammatory treatment on clinical parameters and serum levels of C-reactive protein and proinflammatory cytokines in subjects with periodontitis. *J Periodontol* [Internet]. 2009 Jun;80(6):892–900. Available from: <http://dx.doi.org/10.1902/jop.2009.080552>
65. Zimmermann GR, Avery W, Finelli AL, Farwell M, Fraser CC, Boris AA. Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug. *Arthritis Res Ther* [Internet]. 2009 Jan 26;11(1):R12. Available from: <http://dx.doi.org/10.1186/ar2602>
66. Macatangay BJC, Jackson EK, Abebe KZ, Comer D, Cyktor J, Klamar-Blain C, et al. A randomized, placebo-controlled, pilot clinical trial of dipyridamole to decrease HIV-associated chronic inflammation. *J Infect Dis* [Internet]. 2020;221(10):1598–606. Available from: <http://dx.doi.org/10.1093/infdis/jiz344>
67. Granat F, Monzali C, Jeunesse E, Guerlin M, Trumel C, Geffré A, et al. Comparison of different anticoagulant associations on haemostasis and biochemical analyses in feline blood specimens. *J Feline Med Surg* [Internet]. 2017 Apr;19(4):394–402. Available from: <http://dx.doi.org/10.1177/1098612X16628579>
68. Granat FA, Geffré A, Lucarelli LA, Braun J-PD, Trumel C, Bourges-Abella NH. Evaluation of CTAD (citrate-theophylline-adenosine-dipyridamole) as a universal anticoagulant in dogs. *J Vet Diagn Invest* [Internet]. 2017 Sep;29(5):676–82. Available from: <http://dx.doi.org/10.1177/1040638717713793>
69. Yokota M, Tatsumi N, Tsuda I, Nishioka T, Takubo T. CTAD as a universal anticoagulant. *J Autom Methods Manag Chem* [Internet]. 2003;25(1):17–20. Available from: <http://dx.doi.org/10.1155/S1463924603000038>
70. Copeland H, Nolan PE, Covington D, Gustafson M, Smith R, Copeland JG. A method for anticoagulation of children on mechanical circulatory support. *Artif Organs* [Internet]. 2011 Nov;35(11):1018–23. Available from: <http://dx.doi.org/10.1111/j.1525-1594.2011.01391.x>
71. Gomes OM, Gomes ES. Dipyridamole and low doses of heparin as a new successful physiopathologic and therapeutic approach in 2 cases of disseminated intravascular coagulation. *Heart Surg Forum* [Internet]. 2010 Feb;13(1):E49–51. Available from: <http://dx.doi.org/10.1532/HSF98.20091134>
72. Asakura M, Asanuma H, Kim J, Liao Y, Nakamaru K, Fujita M, et al. Impact of adenosine receptor signaling and metabolism on pathophysiology in patients with chronic heart failure. *Hypertens Res* [Internet]. 2007 Sep;30(9):781–7. Available from: <http://dx.doi.org/10.1291/hypres.30.781>
73. Kitakaze M, Minamino T, Node K, Takashima S, Funaya H, Kuzuya T, et al. Adenosine and cardioprotection in the diseased heart. *Jpn Circ J* [Internet]. 1999 Apr;63(4):231–43. Available from: <http://dx.doi.org/10.1253/jcj.63.231>
74. Riksen NP, Rongen GA, Blom HJ, Boers GHJ, Smits P. Reduced adenosine receptor stimulation as a pathogenic factor in hyperhomocysteinemia. *Clin Chem Lab Med* [Internet]. 2005;43(10):1001–6. Available from: <http://dx.doi.org/10.1515/CCLM.2005.175>
75. Sanada S, Asanuma H, Koretsune Y, Watanabe K, Nanto S, Awata N, et al. Long-Term Oral Administration of Dipyridamole Improves Both Cardiac and Physical Status in Patients with Mild to Moderate Chronic Heart

- Failure: A Prospective Open-Randomized Study [Internet]. Vol. 30, Hypertension Research. 2007. p. 913–9. Available from: <http://dx.doi.org/10.1291/hypres.30.913>
76. Kuo K-L, Hung S-C, Tseng W-C, Liu J-S, Lin M-H, Hsu C-C, et al. Dipyridamole decreases dialysis risk and improves survival in patients with pre-dialysis advanced chronic kidney disease. *Oncotarget* [Internet]. 2018 Jan 12;9(4):5368–77. Available from: <http://dx.doi.org/10.18632/oncotarget.19850>
77. Hung C-C, Yang M-L, Lin M-Y, Lin HY-H, Lim L-M, Kuo H-T, et al. Dipyridamole treatment is associated with improved renal outcome and patient survival in advanced chronic kidney disease. *Kaohsiung J Med Sci* [Internet]. 2014 Dec;30(12):599–607. Available from: <http://dx.doi.org/10.1016/j.kjms.2014.10.002>
78. Lee G, Choong HL, Chiang G, Woo KT. Three-year randomized controlled trial of dipyridamole and low-dose warfarin in patients with IgA nephropathy and renal impairment [Internet]. Vol. 3, Nephrology. 1997. p. 117–21. Available from: <http://dx.doi.org/10.1111/j.1440-1797.1997.tb00201.x>
79. Beaufls M, Uzan S, Donsimoni R, Colau JC. Prospective controlled study of early antiplatelet therapy in prevention of preeclampsia. *Adv Nephrol Necker Hosp* [Internet]. 1986;15:87–94. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/3082120>
80. Shionogi, Inc. Fenofibrate [Triglide]: Highlights of Prescribing Information [Internet]. 2012. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021350s013lbl.pdf
81. Balakumar P, Sambathkumar R, Mahadevan N, Muhsinah AB, Alsayari A, Venkateswaramurthy N, et al. Molecular targets of fenofibrate in the cardiovascular-renal axis: A unifying perspective of its pleiotropic benefits. *Pharmacol Res* [Internet]. 2019 Jun;144:132–41. Available from: <http://dx.doi.org/10.1016/j.phrs.2019.03.025>
82. Grammatikos G, Farnik H, Bon D, Böhlig A, Bader T, Berg T, et al. The impact of antihyperlipidemic drugs on the viral load of patients with chronic hepatitis C infection: a meta-analysis. *J Viral Hepat* [Internet]. 2014 Aug;21(8):533–41. Available from: <http://dx.doi.org/10.1111/jvh.12274>
83. Tomizawa A, Hattori Y, Inoue T, Hattori S, Kasai K. Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation. *Metabolism* [Internet]. 2011 Apr;60(4):513–22. Available from: <http://dx.doi.org/10.1016/j.metabol.2010.04.020>
84. Usui-Ouchi A, Ouchi Y, Ebihara N. The peroxisome proliferator-activated receptor pan-agonist bezafibrate suppresses microvascular inflammatory responses of retinal endothelial cells and vascular endothelial growth factor production in retinal pigmented epithelial cells. *Int Immunopharmacol* [Internet]. 2017 Nov;52:70–6. Available from: <http://dx.doi.org/10.1016/j.intimp.2017.08.027>
85. Terasawa T, Aso Y, Omori K, Fukushima M, Momobayashi A, Inukai T. Bezafibrate, a peroxisome proliferator-activated receptor α agonist, decreases circulating CD14⁺ CD16⁺ monocytes in patients with type 2 diabetes. *Transl Res*. 2015 Feb;165(2):336–45.
86. Huang W-P, Yin W-H, Chen J-S, Huang P-H, Chen J-W, Lin S-J. Fenofibrate reverses dysfunction of EPCs caused by chronic heart failure. *J Cardiovasc Transl Res* [Internet]. 2019;13(2):158–70. Available from: <http://dx.doi.org/10.1007/s12265-019-09889-y>
87. Oidor-Chan VH, Hong E, Pérez-Severiano F, Montes S, Torres-Narváez JC, Del Valle-Mondragón L, et al. Fenofibrate plus metformin produces cardioprotection in a type 2 diabetes and acute myocardial infarction model. *PPAR Res* [Internet]. 2016 Mar 16;2016:1–14. Available from: <http://dx.doi.org/10.1155/2016/8237264>
88. Jakob T, Nordmann AJ, Schandelmaier S, Ferreira-González I, Briel M. Fibrates for primary prevention of cardiovascular disease events. *Cochrane Database Syst Rev* [Internet]. 2016 Nov 16;11:CD009753. Available from: <http://dx.doi.org/10.1002/14651858.CD009753.pub2>
89. Wang D, Liu B, Tao W, Hao Z, Liu M. Fibrates for secondary prevention of cardiovascular disease and stroke. *Cochrane Database Syst Rev* [Internet]. 2015 Oct 25;(10):CD009580. Available from: <http://dx.doi.org/10.1002/14651858.CD009580.pub2>

90. Jonkers IJ, de Man FH, van Tilburg NH, van der Laarse A, Sandset PM, Smelt AH, et al. Alterations in the extrinsic pathway in hypertriglyceridemia do not cause a "procoagulant state": effects of bezafibrate therapy. *Blood Coagul Fibrinolysis* [Internet]. 2001 Dec;12(8):705–12. Available from: <http://dx.doi.org/10.1097/00001721-200112000-00013>
91. Ceska R, Sobra J, Kvasnicka J, Procházková R, Kvasilová M, Haas T. [The effect of micronized fenofibrate on lipid parameters and fibrinogen in heterozygous familial hypercholesterolemia and familial combined hyperlipidemia]. *Cas Lek Cesk* [Internet]. 1996 Jul 26;135(13):413–6. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/8925538>
92. Durrington PN, Mackness MI, Bhatnagar D, Julier K, Prais H, Arrol S, et al. Effects of two different fibrin acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia. *Atherosclerosis* [Internet]. 1998 May;138(1):217–25. Available from: [http://dx.doi.org/10.1016/s0021-9150\(98\)00003-3](http://dx.doi.org/10.1016/s0021-9150(98)00003-3)
93. Sahebkar A, Serban M-C, Mikhailidis DP, Toth PP, Muntner P, Ursoniu S, et al. Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis. *Pharmacol Res* [Internet]. 2016 Jan;103:236–52. Available from: <http://dx.doi.org/10.1016/j.phrs.2015.12.001>
94. Maison P, Mennen L, Sapinho D, Balkau B, Sigalas J, Chesnier M-C, et al. A pharmacoepidemiological assessment of the effect of statins and fibrates on fibrinogen concentration. *Atherosclerosis* [Internet]. 2002 Jan;160(1):155–60. Available from: [http://dx.doi.org/10.1016/s0021-9150\(01\)00552-4](http://dx.doi.org/10.1016/s0021-9150(01)00552-4)
95. Madrid-Miller A, Moreno-Ruiz LA, Borrayo-Sánchez G, Almeida-Gutiérrez E, Martínez-Gómez DF, Jáuregui-Aguilar R. Impact of bezafibrate treatment in patients with hyperfibrinogenemia and ST-elevation acute myocardial infarction: a randomized clinical trial. *Cir Cir* [Internet]. 2010 May;78(3):229–37. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/20642906>
96. Kilicarslan A, Yavuz B, Guven GS, Atalar E, Sahiner L, Beyazit Y, et al. Fenofibrate improves endothelial function and decreases thrombin-activatable fibrinolysis inhibitor concentration in metabolic syndrome. *Blood Coagul Fibrinolysis* [Internet]. 2008 Jun;19(4):310–4. Available from: <http://dx.doi.org/10.1097/MBC.0b013e3283009c69>
97. Ueno H, Saitoh Y, Mizuta M, Shiiya T, Noma K, Mashiba S, et al. Fenofibrate ameliorates insulin resistance, hypertension and novel oxidative stress markers in patients with metabolic syndrome. *Obes Res Clin Pract* [Internet]. 2011 Oct;5(4):e267–360. Available from: <http://dx.doi.org/10.1016/j.orcp.2011.03.012>
98. Pfizer, Inc. Sildenafil citrate [Viagra]: Highlights of Prescribing Information [Internet]. 2017 [cited 2020 Apr 10]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/20895s039s0421bl.pdf
99. Pfizer, Inc. Sildenafil citrate [Revatio]: Highlights of Prescribing Information [Internet]. 2014 Jan. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021845s011,022473s004,0203109s0021bl.pdf
100. Kniotek M, Boguska A. Sildenafil Can Affect Innate and Adaptive Immune System in Both Experimental Animals and Patients. *J Immunol Res* [Internet]. 2017 Feb 20;2017:4541958. Available from: <http://dx.doi.org/10.1155/2017/4541958>
101. Clinicaltrials.gov. Identifier NCT04304313, A Pilot Study of Sildenafil in COVID-19 [Internet]. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US); 2020 [cited 2020 Aug 28]. Available from: <https://clinicaltrials.gov/ct2/show/NCT04304313>
102. Santi D, Giannetta E, Isidori AM, Vitale C, Aversa A, Simoni M. Therapy of endocrine disease. Effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: a meta-analysis. *Eur J Endocrinol* [Internet]. 2015 Mar;172(3):R103–14. Available from: <http://dx.doi.org/10.1530/EJE-14-0700>
103. Aversa A, Vitale C, Volterrani M, Fabbri A, Spera G, Fini M, et al. Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes. *Diabet Med* [Internet]. 2008

- Jan;25(1):37–44. Available from: <http://dx.doi.org/10.1111/j.1464-5491.2007.02298.x>
104. Tzoumas N, Farrah TE, Dhaun N, Webb DJ. Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease. *Br J Pharmacol* [Internet]. 2019 Nov 12;2020:1–22. Available from: <http://dx.doi.org/10.1111/bph.14920>
105. Mostafa T. Non-Sexual Implications of Phosphodiesterase Type 5 Inhibitors [Internet]. Vol. 5, Sexual Medicine Reviews. 2017. p. 170–99. Available from: <http://dx.doi.org/10.1016/j.sxmr.2016.02.004>
106. Hutchings DC, Anderson SG, Caldwell JL, Trafford AW. Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection? *Heart* [Internet]. 2018 Aug;104(15):1244–50. Available from: <http://dx.doi.org/10.1136/heartjnl-2017-312865>
107. Brown KE, Dhaun N, Goddard J, Webb DJ. Potential therapeutic role of phosphodiesterase type 5 inhibition in hypertension and chronic kidney disease. *Hypertension* [Internet]. 2014 Jan;63(1):5–11. Available from: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.113.01774>
108. Anderson S, Hutchings D, Woodward M, Rahimi K, Rutter MK, Kirby M, et al. Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality. *Heart* [Internet]. 2016;102(21):1750–6. Available from: <http://dx.doi.org/10.1136/heartjnl-2015-309223>
109. Barnes H, Brown Z, Burns A, Williams T. Phosphodiesterase 5 inhibitors for pulmonary hypertension. *Cochrane Database Syst Rev* [Internet]. 2019 Jan 31;1:CD012621. Available from: <http://dx.doi.org/10.1002/14651858.CD012621.pub2>
110. Rochwerf B, Neupane B, Zhang Y, Garcia CC, Raghu G, Richeldi L, et al. Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. *BMC Med* [Internet]. 2016 Feb 3;14(1):18. Available from: <http://dx.doi.org/10.1186/s12916-016-0558-x>
111. Ashworth AJ. Enhanced recovery from respiratory infection following treatment with a PDE-5 inhibitor: a single case study. *Prim Care Respir J* [Internet]. 2012 Mar;21(1):17. Available from: <http://dx.doi.org/10.4104/pcrj.2012.00016>
112. Webb DJ, Vachieri J-L, Hwang L-J, Maurey JO. Sildenafil improves renal function in patients with pulmonary arterial hypertension. *Br J Clin Pharmacol* [Internet]. 2015 Aug;80(2):235–41. Available from: <http://dx.doi.org/10.1111/bcp.12616>
113. Clinicaltrials.gov. Identifier NCT04410328, Aggrenox To Treat Acute Covid-19 [Internet]. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US); 2020 [cited 2020 Aug 28]. Available from: <https://ClinicalTrials.gov/show/NCT04410328>
114. Clinicaltrials.gov. Identifier NCT04391179, Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19 [Internet]. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US); 2020 [cited 2020 Aug 28]. Available from: <https://ClinicalTrials.gov/show/NCT04391179>
115. Clinicaltrials.gov. Identifier NCT04424901, Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19 [Internet]. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US); 2020 [cited 2020 Aug 28]. Available from: <https://ClinicalTrials.gov/show/NCT04424901>
116. Hogan RB, Cannon T, Rappi M, Studdard J, Paul D, Dooley TP. Dual-histamine blockade with cetirizine-famotidine reduces pulmonary symptoms in COVID-19 patients. *Pulmonary Pharmacology & Therapeutics* [Internet]. 2020;1–27. Available from: <http://dx.doi.org/10.1016/j.pupt.2020.101942>
117. Janowitz T, Gablenz E, Pattinson D, Wang TC, Conigliaro J, Tracey K, et al. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. *Gut* [Internet]. 2020;69:1592–7. Available from: <http://dx.doi.org/10.1136/gutjnl-2020-321852>
118. Tomera K, Kittah J. Famotidine with celecoxib adjuvant therapy on hospitalized COVID-19 patients: A case series. *SSRN* [Internet]. 2020;1–23. Available from: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3646583

119. Freedberg DE, Conigliaro J, Wang TC, Tracey KJ, Callahan MV, Abrams JA, et al. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study. *Gastroenterology* [Internet]. 2020 May 22;20:1–3. Available from: <https://pubmed.ncbi.nlm.nih.gov/32446698>
120. Malone RW, Tisdall P, Fremont-Smith P, Liu Y, Huang X-P, White KM, et al. COVID-19: famotidine, histamine, mast cells, and mechanisms. *Res Sq* [Internet]. 2020;1–37. Available from: <http://dx.doi.org/10.21203/rs.3.rs-30934/v2>
121. Ehrlich A, Uhl S, Ioannidis K, Hofree M, tenOever BR, Nahmias Y. The SARS-CoV-2 transcriptional metabolic signature in lung epithelium. *SSRN* [Internet]. 2020 Jul 14 [cited 2020 Aug 30];1–27. Available from: <https://papers.ssrn.com/abstract=3650499>
122. Isidori AM, Giannetta E, Pofi R, Venneri MA, Gianfrilli D, Campolo F, et al. Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection. The DEDALO project. *Andrology* [Internet]. 2020;00:1–6. Available from: <http://dx.doi.org/10.1111/andr.12837>
123. Clinicaltrials.gov. Identifier NCT04489446, Sildenafil in COVID-19 [Internet]. ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US); 2020 [cited 2020 Aug 28]. Available from: <https://ClinicalTrials.gov/show/NCT04489446>